Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

RCT (n=621) reported neratinib plus capecitabine significantly improved PFS (HR 0.76; 95% CI, 0.63 to 0.93; P = 0.0059) and OS (HR 0.88; 95% CI, 0.72 to 1.07; P = 0.2098) vs lapatinib plus capecitabine with fewer interventions for CNS disease (22.8% v 29.2%; P = 0.043).

Journal of Clinical Oncology